Journal
CHEMICAL BIOLOGY & DRUG DESIGN
Volume 90, Issue 6, Pages 1067-1078Publisher
WILEY
DOI: 10.1111/cbdd.13030
Keywords
drug design; FBDD; fragment; hit; neglected diseases; screening
Funding
- Sao Paulo State Research Foundation (FAPESP) [2013-15650-0]
- National Council for Scientific and Technological Development (CNPq) [312009/2014-3, 477002/2013-7]
Ask authors/readers for more resources
Neglected diseases (NDs) affect large populations and almost whole continents, representing 12% of the global health burden. In contrast, the treatment available today is limited and sometimes ineffective. Under this scenery, the Fragment-Based Drug Discovery emerged as one of the most promising alternatives to the traditional methods of drug development. This method allows achieving new lead compounds with smaller size of fragment libraries. Even with the wide Fragment-Based Drug Discovery success resulting in new effective therapeutic agents against different diseases, until this moment few studies have been applied this approach for NDs area. In this article, we discuss the basic Fragment-Based Drug Discovery process, brief successful ideas of general applications and show a landscape of its use in NDs, encouraging the implementation of this strategy as an interesting way to optimize the development of new drugs to NDs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available